
In this interview we discuss findings from M12-356, an open-label, phase I, escalation cohort study of the investigational anti-EGFR antibody-drug conjugate ABT-414 for patients with EGFR-amplified recurrent glioblastoma.

Your AI-Trained Oncology Knowledge Connection!


Published: November 21st 2016 | Updated: